Parkinson's disease psychosis management: an evidence based, experience informed, pragmatic approach

JH Friedman - Expert Opinion on Pharmacotherapy, 2024 - Taylor & Francis
Introduction Psychotic symptoms in people with Parkinson's disease (PD) have attracted
increasing. Recommendations on treating psychosis often fail to take into account what …

[HTML][HTML] Clozapine is severely underused in Parkinson's disease patients

JH Friedman - Movement disorders clinical practice, 2022 - ncbi.nlm.nih.gov
Clozapine is a unique drug for people with Parkinson's disease (PD). It was the first drug
shown to be an effective antipsychotic that did not worsen motor function. 1, 2 It was the first …

Can clozapine be used for treatment-refractory behavioral and psychological symptoms in dementia patients?

PFJ Schulte - Schizophrenia Research, 2023 - Elsevier
Behavioral and psychological symptoms of dementia (BPSD), including agitation, psychosis
and aggression, sleep problems, wandering and various inappropriate behaviors, are …

Brief commentary: Under-recognition of underuse of clozapine in treating psychotic symptoms in Parkinson's disease

JH Friedman - Schizophrenia Research, 2023 - Elsevier
Clozapine is an important drug in the treatment of Parkinson's disease (PD). It has proven
efficacy in treating PD psychosis without worsening motor function, as well as in treating …

[PDF][PDF] Μέτρηση βιολογικών δεικτών σε ασθενείς με σχιζοφρένεια πριν και μετά τη θεραπεία με κλοζαπίνη

Α Καραμπάς - 2023 - olympias.lib.uoi.gr
ΜΕΤΡΗΣΗ ΒΙΟΛΟΓΙΚΩΝ ΔΕΙΚΤΩΝ ΣΕ ΑΣΘΕΝΕΙΣ ΜΕ ΣΧΙΖΟΦΡΕΝΕΙΑ ΠΡΙΝ ΚΑΙ ΜΕΤ Page 1
ΠΑΝΕΠΙΣΤΗΜΙΟ ΙΩΑΝΝΙΝΩΝ ΣΧΟΛΗ ΕΠΙΣΤΗΜΩΝ ΥΓΕΙΑΣ ΤΜΗΜΑ ΙΑΤΡΙΚΗΣ ΤΟΜΕΑΣ …

Preventing α-Synuclein aggregation. Finding disease modifying molecules for Parkinson's disease

S Peña Díaz - 2022 - tdx.cat
Neurodegenerative disorders, such as Parkinson's or Alzheimer's diseases, are one of the
biggest health challenges in modern society. The lack of effective treatments and early …